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Abstract We report a British family with young-onset
Parkinson’s disease (PD) and a G51D SNCA mutation that
segregates with the disease. Family history was consistent
with autosomal dominant inheritance as both the father and
sister of the proband developed levodopa-responsive par-
kinsonism with onset in their late thirties. Clinical features
show similarity to those seen in families with SNCA tripli-
cation and to cases of A53T SNCA mutation. Post-mortem
brain examination of the proband revealed atrophy affecting
frontal and temporal lobes in addition to the caudate,
putamen, globus pallidus and amygdala. There was severe
loss of pigmentation in the substantia nigra and pallor of the
locus coeruleus. Neuronal loss was most marked in frontal
and temporal cortices, hippocampal CA2/3 subregions,
substantia nigra, locus coeruleus and dorsal motor nucleus of
the vagus. The cellular pathology included widespread and
frequent neuronal a-synuclein immunoreactive inclusions
of variable morphology and oligodendroglial inclusions
similar to the glial cytoplasmic inclusions of multiple system
atrophy (MSA). Both inclusion types were ubiquitin and p62
positive and were labelled with phosphorylation-dependent
anti-a-synuclein antibodies In addition, TDP-43 immuno-
reactive inclusions were observed in limbic regions and in
the striatum. Together the data show clinical and neuro-
pathological similarities to both the A53T SNCA mutation
and multiplication cases. The cellular neuropathological
H. Houlden, J. L. Holton are senior authors.
Electronic supplementary material The online version of this
article (doi:10.1007/s00401-013-1096-7) contains supplementary
material, which is available to authorized users.
A. P. Kiely (&)  Y. T. Asi  H. Ling  A. J. Lees  J. Hardy 
T. Revesz  J. L. Holton
Queen Square Brain Bank, UCL Institute of Neurology,
London, UK
e-mail: a.kiely@ucl.ac.uk
J. L. Holton
e-mail: janice.holton@ucl.ac.uk
A. P. Kiely  Y. T. Asi  H. Ling  A. J. Lees  J. Hardy 
T. Revesz  J. L. Holton
Department of Molecular Neuroscience, UCL Institute
of Neurology, Queen Square, London, UK
E. Kara  H. Ling  P. Lewis  A. J. Lees  J. Hardy 
H. Houlden
Department of Molecular Neuroscience,
UCL Institute of Neurology, London, UK
E. Kara  H. Ling  P. Lewis  A. J. Lees  J. Hardy 
H. Houlden
Reta Lila Weston Institute of Neurological Studies,
UCL Institute of Neurology, London, UK
P. Limousin
Unit of Functional Neurosurgery, UCL Institute of Neurology,
London, UK
P. Limousin
Sobell Department of Motor Neuroscience and Movement
Disorders, University College London, London, UK
P. Lewis
School of Pharmacy, University of Reading,
Whiteknights, Reading, UK
C. Proukakis
Department of Clinical Neuroscience,
UCL Institute of Neurology, London, UK
N. Quinn
National Hospital for Neurology and Neurosurgery,
Queen Square, London, UK
123
Acta Neuropathol (2013) 125:753–769
DOI 10.1007/s00401-013-1096-7
features of this case share some characteristics of both PD
and MSA with additional unique striatal and neocortical
pathology. Greater understanding of the disease mechanism
underlying the G51D mutation could aid in understanding of
a-synuclein biology and its impact on disease phenotype.
Keywords Parkinson’s disease 
Multiple system atrophy  a-Synuclein  SNCA
Abbreviations
Ab Amyloid beta
ALS Amyotrophic lateral
sclerosis
CA Cornu ammonis
CB Coiled bodies
Cg Cingulate gyrus
CN Caudate nucleus
DF Dentate fascia
DLB Dementia with Lewy
bodies
DMV Dorsal motor nucleus of
the vagus
FTLD Frontotemporal lobar
degeneration
GCI Glial cytoplasmic
inclusions
LB Lewy bodies
LN Lewy neurites
MSA Multiple system atrophy
NAC Non-amyloid-b-
component
NCI Neuronal cytoplasmic
inclusions
NNI Neuronal nuclear
inclusions
PBs Pale bodies
PNs Pale neurites
PD Parkinson’s disease
Pt Putamen
SLM Stratum lacunosum-
moleculare
SN Substantia nigra
TAR-DNA-binding protein-43 TDP-43
WT Wild type
Introduction
The term a-synucleinopathy unites a group of neurode-
generative diseases which share the pathological hallmark
of fibrillary inclusions in which a-synuclein protein is the
major component. The three most common members of
this group are Parkinson’s disease (PD), dementia with
Lewy bodies (DLB) and multiple system atrophy (MSA).
PD and DLB have common neuropathological features
including deposition of fibrillar a-synuclein in Lewy bodies
(LB) and Lewy neurites (LN). In MSA, a-synuclein is
aggregated in oligodendrocytes forming the hallmark
lesion, the glial cytoplasmic inclusion (GCI), and also in
neuronal cytoplasmic inclusions (NCIs), cell processes and
to a lesser extent in neuronal and glial nuclei [1, 28].
Several missense mutations of the SNCA gene have been
identified in families with autosomal dominant forms of
PD. No SNCA mutation has been linked with MSA, how-
ever, polymorphisms of the gene have been associated with
increased risk of the disease in Caucasian populations,
although these results have not been replicated in all pop-
ulations [2, 70, 71, 83]. The SNCA gene, which encodes the
140-amino acid protein a-synuclein, is located on chro-
mosome 4q21-23. In Parkinson’s disease, the first SNCA
mutation to be described was A53T in a Greek-Italian
family [62] and this was subsequently identified in families
of Asian, Swedish and Polish origin [5, 12, 42, 49, 59, 61,
66, 77]. Two further missense mutations of SNCA were
identified, A30P [43] and E46K [84] in German and Bas-
que families, respectively. Very recently, we have reported
the novel H50Q SNCA mutation [65]. Missense mutations
in the N-terminal region of a-synuclein are reported to
have a direct impact on a-synuclein conformation and
function. The A53T and E46K mutant forms of a-synuclein
exhibit faster fibrillisation kinetics than wild-type protein
[12], while fibrillisation of the A30P mutant protein is
slower and results in fewer complex fibrils in LBs [47].
Duplication and triplication of SNCA have been discovered
in a small number of families and sporadic cases of levo-
dopa-responsive PD and, where described, pathological
features of PD, in addition to GCIs similar to those of
MSA, are observed [10, 22, 27, 31, 32, 55, 56]. The number
of SNCA locus replicates is known to influence disease
progression, such that triplication causes earlier onset and a
more rapid clinical course than SNCA duplication [31, 75].
Pathological inclusions of fibrillar a-synuclein have
distinct morphologies and distribution depending on disease
type. For example, in PD, the characteristic LBs and LNs
occur in brainstem nuclei and usually exhibit a hierarchical
spread to involve limbic and neocortical regions with dis-
ease progression [8], although not all cases conform to the
proposed pattern of disease progression [36]. In MSA, GCIs
are the most abundant form of fibrillar a-synuclein inclu-
sion and together with neuronal cytoplasmic or nuclear
inclusions are distributed widely in the striatonigral, oli-
vopontocerebellar and other regions [1, 4, 33, 60].
We report a family with young-onset PD and a mutation
in SNCA that segregates with the disease. We describe an
a-synucleinopathy with both PD and MSA-like
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neuropathological features together with involvement of
the striatum and severe CA2/3 neuronal loss. The distri-
bution of neuronal and oligodendroglial inclusions
immunoreactive for a-synuclein, ubiquitin and p62 is
described. The phosphorylation state of a-synuclein within
inclusions and the relationship of a-synuclein to intracel-
lular accumulation of tau and TDP-43 are also investigated.
Together the evidence reveals neuropathological similari-
ties to both the A53T SNCA mutation and multiplication
cases with additional unique striatal and neocortical
pathology [27, 48].
Materials and methods
Brain tissue
The brain was donated to the Queen Square Brain Bank for
Neurological Disorders, UCL Institute of Neurology using
ethically approved protocols and stored for research under
a licence issued by the Human Tissue Authority (No.
12198). Following fixation in 10 % buffered formalin, the
right half brain was sliced in the coronal plane, examined
and blocks were selected for paraffin wax embedding and
histology.
Paraffin-embedded sections (8 lm) were stained using
haematoxylin and eosin (H&E), Luxol fast blue/cresyl
violet and Gallyas silver impregnation. Immunohisto-
chemistry was performed as previously described [58]
using primary antibodies detailed in Online Resource 1.
Double immunofluorescence was detected using isotype
specific anti-rabbit IgG or anti-mouse IgG secondary
antibodies conjugated with either Alexa 488 or 594 fluo-
rescent dyes (1:400) (Life technologies, Paisley, UK)
followed by quenching of autofluorescence with 0.1 %
Sudan Black/70 % ethanol (Sigma-Aldrich, Dorset, UK)
solution for 10 min and mounting with glass coverslips
using VECTAshield mounting media with 40,6-diamidino-
2-phenylindole (DAPI) nuclear stain (Vector laboratories,
Peterborough, UK). Images were visualised using confocal
fluorescence microscopy (Leica DM5500 B).
Genetics
Sanger sequencing was performed for exon 3 of SNCA on
family members for whom a DNA sample was available
(affected sibling and unaffected mother). Genomic DNA
was amplified through polymerase chain reaction (PCR)
with the Roche Fast start master mix kit (primer sequences
available upon request). After purification, the PCR prod-
uct was sequenced bi-directionally with the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied biosys-
tems). Purified sequencing reaction products were run on
ABI 3730xl DNA analyser, sequencing results were
analysed on Sequencher version 4.1.4 and variants identi-
fied were named based on the GenBank reference sequence
with accession numbers NM_001146055.1 and NP_
001139527.1. Variants identified were verified through
re-sequencing a duplicate genomic DNA sample. To
exclude larger genomic rearrangements in the SNCA
region, genomic DNA samples from both affected siblings
were run on Illumina Human660W-Quad BeadChip arrays
and the results were analysed on Illumina Genome studio
V2010.2.
Sequence alignment
Amino acid sequence data for a-synuclein from Homo
sapiens, Pan troglodytes, Sus scrofa, Mus musculus, Bos
taurus, Xenopus laevis and Gallus gallus, along with amino
acid sequence data for human b and c synuclein, were
downloaded from NCBI. Sequence alignment was carried
out using the basic local alignment search tool (BLAST,
http://blast.ncbi.nlm.nih.gov). Secondary structure data
for a-synuclein are based upon data from Ulmer and
coworkers [80].
Results
Case history
At age 19, this British man presented with stiffness and
tremor in his left hand. Examination revealed a classical
parkinsonian rest tremor of the left arm and leg with bra-
dykinesia, cogwheel rigidity and reduced left arm swing on
walking. Eye movements were normal. His symptoms
gradually involved his right side and he had a parkinsonian
gait. At age 25, levodopa therapy was started with a good
initial response, but 7 months later, he developed levo-
dopa-induced choreiform movements which continued to
be troublesome for a decade. Since age 28, he had pro-
gressive cognitive impairment with a mini mental state
examination (MMSE) score of 24/30 at age 30 and 19/30 at
age 32, neuropsychometry showed visual and verbal
memory impairments and he later developed visual hallu-
cination. At age 33, he was incapacitated by severe
dysarthria, severe akinetic rigidity, postural hypotension
with syncope and postural instability. Examination
revealed limb myoclonus, spasticity and bilateral extensor
plantar response. He started to have seizures in the last
8 years of his life but these were controlled using sodium
valproate. He died at age 49 with a disease duration of
29 years.
His father died of a similar illness with onset of motor
symptoms at age 39 and later developed dementia and died
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of sepsis at age 47. His sister developed parkinsonism at
age 40 and has had a good persistent levodopa response.
She is now 48 years old and has mild peak dose dyskinesia,
occasional visual hallucination and has not noted any
cognitive impairment. The case history of the proband was
previously published in a series on young onset Parkinson’s
disease (case 2M) [67].
Genetics
In the affected family members, an a-synuclein G [ A het-
erozygous mutation at base 152, codon 51 causing a glycine
to aspartic acid amino acid change (Fig. 1a). This mutation
segregated with the disease in the family (Fig. 1b) and was
not seen in over 4,500 control individuals. Multiplication of
the a-synuclein gene had been previously excluded by SNP
array analysis. The mutated amino acid is highly conserved
across species down to invertebrates and is predicted to be
damaging using PolyPhen-2 and SIFT (Fig. 2).
Neuropathological findings
The brain weighed 1,036 g and showed frontal and anterior
temporal lobe atrophy (Fig. 3a, b). The hippocampus,
amygdala, caudate, putamen and globus pallidus were
reduced in volume and showed greyish discolouration
(Fig. 3a, b). The subthalamic nucleus was of normal size
with mild brown discolouration (Fig. 3b). There was severe
loss of pigmentation of the substantia nigra (Fig. 3c, arrow)
and mild pallor of the locus coeruleus (Fig. 3d, arrow). The
medulla and cerebellum were macroscopically unremark-
able (Fig. 3e).
Histological findings
Histological findings are summarised in Table 1 and
illustrated in Figs. 4 and 5. The neocortical regions showed
marked superficial vacuolation with neuronal loss and
gliosis in all regions except the occipital cortex. Cortical
neuronal depletion was most severe in the anterior tem-
poral, piriform and insular cortices. In the hippocampal
formation, neuronal loss affected all regions except the
dentate fascia (DF) and this was most striking and severe in
the CA2 and CA3 subregions where there was almost
complete neuronal loss with accompanying gliosis. Mild
neuronal loss accompanied by severe and uniformly dis-
tributed gliosis was observed in the caudate and putamen
(Fig. 4i, j). There were virtually no remaining pigmented
neurons in the substantia nigra pars compacta (Fig. 4h),
and there was severe loss of neurons in the locus coeruleus
and the dorsal motor nucleus of the vagus (DMV). No
classical intraneuronal LBs were seen in the substantia
nigra, locus coeruleus or DMV in H&E stained sections,
likely due to the very severe neuronal loss. Cerebellar
Purkinje cells were moderately depleted while the dentate
nucleus was well preserved. In the rostral cervical spinal
cord, the anterior horn motor neurons were preserved.
Weakly basophilic NCIs with varied morphology, includ-
ing well-defined round or oval structures and perinuclear
annular or crescent shapes, were widespread and were
prominent in the hippocampus, neocortex and striatum
(Fig. 4a–k). Balloon neurons, best identified by aB-crys-
tallin immunohistochemistry, were present in the frontal
and temporal cortices and were most numerous in the
cingulate gyrus (Fig. 4g).
Fig. 1 SNCA mutation G51D. Chromatogram (red thymine, blue
cytosine, green adenine and black guanine). Sanger sequencing of the
SNCA gene identified a c.G152A mutation (upper arrows) in exon 3
of this gene as shown. This created a glycine to aspartic acid amino
acid change (lower arrows)
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Distribution and morphology of a-synuclein
immunoreactive inclusions
Immunohistochemical staining for a-synuclein demon-
strated widespread neuronal and glial inclusions (Table 1;
Fig. 5). Amongst the areas most severely affected by
neuronal a-synuclein pathology was the hippocampus
(Fig. 5a–d), in which the DF and CA1 contained many
inclusions. Inclusions were sparse in the CA2 and CA3
subregions reflecting the paucity of residual neurons in these
areas. The caudate and putamen contained a remarkable
load of neuronal a-synuclein-positive inclusions affecting
all regions of each nucleus to a similar extent (Fig. 5e, f). In
the neocortex, there was a distinct pattern in which the
superficial and deep cortical laminae were most severely
affected (Fig. 5g, h). NCIs had variable morphology; many
were clearly defined globular inclusions resembling LBs
(Fig. 5i), while others were annular or crescent shaped sit-
uated around the nucleus (Fig. 5j), less frequently they
resembled neurofibrillary tangles (Fig. 5k). Small numbers
of neurons showed a diffuse finely granular pattern of
a-synuclein immunoreactivity (Fig. 5l). In most areas,
neuronal inclusions were accompanied by threads of varying
width, up to 10 lm, representing a-synuclein accumulation
in cell processes. In cross section, these appeared as dots and
round–oval structures. The argyrophilic nature of fibrillar
a-synuclein inclusions was demonstrated using Gallyas
silver impregnation (Fig. 5m–o).
Glial inclusions
A significant numbers of glial, a-synuclein-positive inclu-
sions were observed, many of which resembled the GCIs of
MSA (Fig. 6a–d) and thus are hereafter referred to as GCI-
like, while others had appearances similar to coiled bodies
(CBs) as previously described in PD [81]. The distribution
of GCI-like pathology also resembled MSA as they were
most frequent in the pontine base, cerebellar white matter
and in the white matter underlying the motor cortex
(Table 1). They were also immunoreactive for recognised
GCI markers including aB-crystallin [63]. Double immu-
nofluorescence of a-synuclein with the oligodendroglial
marker olig-2 confirmed that GCI-like inclusions were in
oligodendrocytes (Fig. 6a–d).
Fig. 2 a-Synuclein protein structure and conservation as shown by
amino acid sequence alignment. Amino acid sequence of human
a-synuclein, showing regions of secondary structure (alpha helices
highlighted in green). The G51 residue is indicated by an arrow, and
sits in the middle of helix 2 (a). Sequence alignment of a-synuclein
amino acid sequences from Homo sapiens, Pan troglodytes, Sus
scrofa, Mus musculus, Bos taurus, Xenopus laevis and Gallus gallus.
The G51 residue highlighted in yellow and indicated by an arrow is
conserved throughout these organisms (b). Sequence alignment of
human a-, b- and c-synuclein amino acid sequences, with the G51
residue is highlighted in yellow and indicated by an arrow (c). This
residue is conserved in a- and b-synuclein, but is replaced by a serine
residue in c-synuclein
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The relationship between microglia and astrocytes with
a-synuclein pathology was also investigated. A subset of
microglia, detected using the microglial marker iba-1, was
observed in close proximity to, in some cases with pro-
cesses encircling, a-synuclein inclusion containing neurons
(Fig. 6e–g). A small number of microglia investigated in
both the hippocampus and neocortex contained thread-like
a-synuclein immunoreactivity (Fig. 6g inset, arrows). Marked
reactive astrogliosis, detected by GFAP immunofluorescence,
was observed, however, double immunofluorescence
studies showed no a-synuclein immunoreactivity in astro-
cytic processes in any regions including the severely
affected CA2, where there was a high density of a-syn-
uclein-positive threads (Fig. 6h–j).
Fig. 3 Macroscopic features. Macroscopic images of formalin fixed
right hemispheric brain slices (a, b), midbrain (c), pons (d) and
cerebellum (e). There was severe atrophy of the temporal cortex with
relative preservation of the superior temporal gyrus (a, b) and severe
reduction in volume of white matter with thinning of the corpus
callosum (a, b white asterisks). The caudate nucleus was reduced in
volume (a, b arrow heads). There was reduction in size and grey
discolouration of both the putamen and the globus pallidus (a, b). The
amygdala was small and darkly coloured (a, black asterisk). The
hippocampus was moderately reduced in volume (b). The midbrain
showed marked depigmentation of the substantia nigra (c, arrow).
The pons was well preserved with severe pallor of the locus coeruleus
(d, arrow). The cerebellum was macroscopically normal and the
white matter was well preserved (e). Scale bars represent 15 mm
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Table 1 Semi-quantitative assessment and regional distribution of neuronal loss and a-synuclein pathology
Neuronal loss Neuronal a-synuclein pathology a-Synuclein
threads
Oligodendroglial
a-synuclein inclusions
Annular or
crescent
Globular Diffuse NFT-like
Cortex
Frontal ? ?? ? ? – ?? ?
Motor ? ?? ? ? – ??? ?
Temporal ??? ??? ? ? – ??? –
Parietal ? ??? ?? ? – ??? –
Occipital – ? – – – – –
Cingulate ?? ??? ?? ? – ??? –
Insular ??? ??? ? ? – ??? –
Sub-cortical white matter
Frontal N/A N/A N/A N/A N/A ? ?
Motor N/A N/A N/A N/A N/A ? ??
Temporal N/A N/A N/A N/A N/A ? ?
Parietal N/A N/A N/A N/A N/A ? ?
Occipital N/A N/A N/A N/A N/A ? –
Cingulate N/A N/A N/A N/A N/A ? ?
Internal capsule N/A N/A N/A N/A N/A ?? ?
External capsule N/A N/A N/A N/A N/A ?? ?
Amygdala ??? ?? ?? ? – ??? ?
Hippocampus
DF – ??? ? ? – ?? –
CA4 ?? ?? ? ? ? ??? ?
CA3 ??? ? ? – – ?? –
CA2 ??? – – – – ?? –
CA1 ? ??? ? ? ? ??? –
Subiculum ? ?? ?? ? ? ??? –
Entorhinal cortex ?? ??? ? ? ? ??? –
Transentorhinal cortex ?? ?? ? ? ? ?? –
Caudate ? ? ??? ?? ? ??? –
Putamen ? ?? ??? ?? ? ??? –
Globus pallidus – ? – – – ? ?
Thalamus – – ? ? – ? ?
Subthalamic nucleus – – – ? – ?? –
Red nucleus – – – – – ? ?
III nerve nucleus – ? ? ? – ? –
Substantia nigra ??? – – – – ?? ?
Locus coeruleus ??? – – – – ?? –
Pontine nuclei – – – ? – ? ?
Pontine base white matter N/A – – – – ?? ??
Dorsal motor nucleus of vagus ??? – – – – ?? –
Twelfth nerve nucleus – – – – – ? –
Inferior olive ? – – ?? – ? –
Cerebellar hemisphere Purkinje cells ?? – – – – – N/A
Cerebellar hemisphere white matter N/A N/A N/A N/A N/A ?? ??
Dentate nucleus – – – – – – –
Cervical cord anterior horn – – – – – – –
Cervical cord white matter N/A N/A N/A N/A N/A ? –
Oligodendroglial a-synuclein: cytoplasmic inclusions usually with similar morphology to GCIs of MSA, less frequently resembling coiled bodies
N/A not applicable, NFT neurofibrillary tangle
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Fig. 4 Histological findings. Representative images from the hippo-
campus (a–e), insular cortex (ins, f), cingulate gyrus (Cg, g),
substantia nigra (SN, h) and putamen (put, i–k). In the hippocampus,
there was severe neuronal loss in the CA2 and CA3 (a, arrows). The
CA2 showed few residual neurons (b). Neuronal inclusions (arrows)
with varying morphology are illustrated in the CA1 (c), CA3 (d) and
the dentate fascia (DF, e). Superficial laminae of the neocortex
showed marked neuronal loss with microvacuolation illustrated in the
insular cortex (ins, f). Ballooned neurons were most frequent in the
cingulate gyrus (Cg, g). The substantia nigra (SN) shows severe loss
of pigmented neurons accompanied by gliosis (h). Abundant eosin-
ophilic reactive astrocytes are visualised in the putamen (put, i) and
confirmed by GFAP immunohistochemistry (j). TDP-43 immunore-
active inclusions were also detected in the putamen (k). Luxol fast
blue (a), haematoxylin and eosin (H&E) (b–f, h, i), aB-crystallin (g),
GFAP (j) TDP-43 (k). Scale bar 150 lm (a), scale bars in b, e–h,
k represent 50 lm (c–e are at the same magnification, as are i–k)
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Tau expression within neuronal inclusions
and co-localisation with a-synuclein
Phosphorylated tau was identified using immunohisto-
chemical staining for AT8, recognising Ser202 and Thr205
(Fig. 7a). This demonstrated granular pre-tangles, neurofi-
brillary tangles and neuropil threads in the hippocampal
formation, most frequent in the CA1, CA4 and subiculum.
They were also present in moderate numbers in the en-
torhinal and transentorhinal cortices and DF (shown in the
DF, Online resource 2). There was no neocortical tau
pathology and only rare neuropil threads were found in the
midbrain and pontine tegmenta. Overall the tau pathology
conformed largely to Braak and Braak stage II Alzheimer-
type pathology, although involvement of the DF at this
stage would not be expected [6]. Further support for Alz-
heimer-type tau deposition was provided using the AT100
antibody, recognising tau phosphorylated at Thr212 and
Ser214 with paired helical filament conformation, which
labelled a proportion of neurofibrillary tangles and by
isoform specific antibodies, which showed a mixture of
3- and 4-repeat tau isoforms (Fig. 7b–d).
Fig. 5 Characterisation of neuronal and glial a-synuclein inclusions.
Thread-like a-synuclein immunoreactivity was observed to be
widespread, shown here within the hippocampal regions CA1, CA3
and CA4 (a–c), caudate nucleus (Cd, e), putamen (put, f) and insular
cortex (ins, g, h). Neuronal cytoplasmic inclusions immunoreactive
for a-synuclein had a number of different morphological appearances
globular (i), annular (j), neurofibrillary tangle-like (k) and diffuse (l).
Gallyas silver impregnation demonstrated the presence of fibrillar
protein in neuronal inclusions (DF, m and CA4, n) and also in GCI-
like inclusions (pontine base, o). Scale bars in e–h, l represent 50 lm
(a–n) (a–e are at the same magnification as are i–l, m and n). Scale
bar in o represents 10 lm
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Double immunofluorescence microscopy was used to
investigate the relationship between a-synuclein and tau.
This showed that, particularly in the CA1 and DF, a-syn-
uclein and tau co-localised in a proportion of inclusions
(Fig. 7e–l). In addition, AT8 immunoreactivity was
detected on the dendritic processes of DF neurons in the
stratum lacunosum-moleculare (SLM), which also expres-
sed a-synuclein (Fig. 7m–p).
a-Synuclein within inclusions is phosphorylated
and inclusions are immunoreactive for ubiquitin
and p62
a-Synuclein in LBs is widely reported to be extensively
phosphorylated [23, 82]. Double immunofluorescence
staining for total a-synuclein and a-synuclein phospho-
Ser129 (Fig. 8a–c) or phospho-Y125 (Fig. 8d–f) showed
Fig. 6 Glial inclusions. Representative double immunofluorescence
images probed with a-synuclein (red) and the oligodendroglial
marker, olig2 (green). Composite merged images show a-synuclein
immunoreactive inclusions in oligodendrocytes resembling GCIs in
the white matter of the frontal cortex (a, d), the pons (b) and the
alveus of the hippocampus (c). Close proximity is observed between a
subset of activated microglia, as detected by iba-1 (green) and
a-synuclein (red) inclusion containing neurons, this occasionally
involved encircling of a-synuclein-containing neurons by iba-1-
positive processes (e–g). A small proportion of these microglia
contained a-synuclein immunoreactivity (g, inset arrowheads). A
high level of reactive astrogliosis was detected throughout all brain
regions examined, without evidence of a-synuclein expression within
astrocytes or their processes (h–j). DAPI nuclear stain (blue). Scale
bar in j represents 50 lm (a–j). Scale bar in g inset represents 25 lm
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almost complete overlap of immunoreactivity within
inclusions, implying the near total phosphorylation of
a-synuclein at both epitopes. Ubiquitin and p62 co-localised
with the majority of neuronal a-synuclein-positive inclu-
sions (Fig. 8g–l) and also GCI-like inclusions (Fig. 8m–o).
Additional pathological findings
TDP-43 immunohistochemistry identified moderate num-
bers of NCIs in the caudate and putamen (Fig. 4k), while
these were sparse in the amygdala, DF, CA4, CA1,
Fig. 7 Tau expression and co-localisation with a-synuclein. Repre-
sentative images from CA1 probed using immunohistochemistry with
phospho-tau antibodies: AT8 (a) and AT100 (b). Inclusions contained
a mixture of 3-repeat (c) and 4-repeat (d) tau isoforms. Double
immunofluorescence images of CA2 (e–i) and DF (j–l) probed for
a-synuclein (green) and AT8 (red) show strong co-localisation in a
subset of neurons. AT8 immunoreactivity is detected on the dendritic
processes of DF granule cells which express a-synuclein in the
stratum lacunosum-moleculare (SLM, m–p). DAPI nuclear stain
(blue). Scale bars represent 50 lm (b–d are at the same magnification
as are e–g, j–o)
Fig. 8 a-Synuclein is phosphorylated and inclusions contain ubiqui-
tin and p62. Representative images of the CA2 region of the
hippocampus probed by double immunofluorescence with total
a-synuclein (red) and a-synuclein phospho-S129 (green) (a–c), or
a-synuclein (green) and a-synuclein phospho-Y125 (red) (d–f) show
near complete co-localisation indicating that a-synuclein is phos-
phorylated at both epitopes. The majority of a-synuclein
immunoreactivity (green) within neuronal inclusions co-localised
with ubiquitin (red), shown in CA1 neurons (g–i). Many a-synuclein-
positive (green) neuronal inclusions also contained P62 (red) (j–l) and
a similar pattern was observed in GCI-like inclusions illustrated in the
white matter underlying the entorhinal cortex (EC, m–o). DAPI
nuclear stain (blue). Scale bars represent 50 lm (a–l are at the same
magnification as are m–o)
c
Acta Neuropathol (2013) 125:753–769 763
123
764 Acta Neuropathol (2013) 125:753–769
123
subiculum, entorhinal cortex and transentorhinal cortex. A
single neuronal nuclear TDP-43 immunoreactive inclusion
was noted in the entorhinal cortex. Ab deposition was not
detected.
Discussion
We provide detailed clinical, genetic and neuropathologi-
cal characterisation of an a-synucleinopathy in a patient
carrying a G51D a-synuclein mutation, clinically diag-
nosed with juvenile parkinsonism. Neuropathological
analysis revealed a combination of the characteristic profile
of SN and LC neuronal loss together with neuronal
a-synuclein immunoreactive inclusions consistent with PD
as well as severe hippocampal, cortical and striatal
a-synuclein pathology. An additional feature was the
presence of GCI-like oligodendroglial inclusions with a
distribution similar to that found in MSA. This case shows
some similarity to reports of A53T mutation and multi-
plication of SNCA (Table 2) and also to a Japanese kindred
reported in an abstract as carrying a G51D SNCA mutation,
but without detailed segregation data [50, 51]. However,
features including dense accumulation of a-synuclein-
positive inclusions in the striatum and very severe neo-
cortical a-synuclein pathology affecting both superficial
and deep cortical laminae distinguish this case from other
reported cases with SNCA mutations.
In comparison with other reported mutations in the
SNCA gene, the age of onset in this family, clinical features
and progression are most similar to the SNCA triplication
[16] and A53T mutations, which are typically associated
with young-onset PD frequently associated with cognitive
impairment and hallucinations. This is similar to the family
where the proband presented early at 19 years while his
father and sister presented at age 39 and 40 years,
respectively.
In this family, an SNCA G [ A heterozygous mutation
at codon 51 causes a glycine to aspartic acid amino acid
change (Fig. 1a), which segregates with the disease
(Fig. 1b) and was not found in over 4,500 control indi-
viduals. The G51D mutation is located in the N-terminal
domain of the protein, a region required for lipid affinity
and membrane binding and may thus influence these
functions (Fig. 2) [20, 37, 68]. As the A53T and E46K
mutations result in faster fibrillisation of a-synuclein
[13, 62], we postulate that the G51D mutation might have a
similar effect.
The neuropathological findings included some features
of both PD and MSA. In common with PD and MSA, there
was severe neuronal loss in the SN. Neuronal a-synuclein
pathology had a distribution compatible with PD in that
brainstem, limbic and cortical regions were affected.
Unusual for PD, however, was the severe neuronal loss in
the CA2/3 subregions of the hippocampus and the exten-
sive accumulation of neuronal a-synuclein in the
hippocampus, including the DF, and striatum [7, 8, 38, 52].
Involvement of the DF by neuronal a-synuclein inclusions
has been described previously in the case of DLB with
additional MSA-type pathology and in some cases of MSA
[73, 74, 78]. The severe neuronal loss observed in CA2/3 of
this case bears similarity to that described in association
with A53T SNCA mutation [48, 77] and in cases of mul-
tiplication of SNCA, though this pattern of loss was
suggested to be a unique feature of the latter [21] (Table 2).
As frequently observed in PD and DLB, and also reported
in conjunction with A53T SNCA mutation, a-synuclein-
positive threads were frequent in CA2/3 [17, 18, 34, 35].
The severe neuronal loss we observed is likely to be
associated with the susceptibility of these hippocampal
subregions to a-synuclein accumulation.
Oligodendroglial pathology in the form of GCI-like
inclusions in regions such as the posterior frontal white
matter, pontine base and cerebellar white matter was also
notable and prompts comparison with MSA. In common
with GCIs in MSA, these inclusions were immunoreactive
for aB-crystallin [63]. Oligodendroglial pathology with
similar morphological appearances has been described in
cases with SNCA multiplication or A53T mutation
(Table 2) and, interestingly, was also reported in a sporadic
DLB case [74]. Neuronal and glial a-synuclein pathology
in the striatum is also a common feature of MSA and we
noted very frequent striatal neuronal a-synuclein immu-
noreactive inclusions coupled with severe gliosis.
However, in notable contrast to MSA, in which the puta-
men has a gradient of pathology most severely affecting the
posterior and dorsal aspects of this nucleus with less severe
involvement of the caudate, there was a uniform distribu-
tion of pathology in all regions of both nuclei in this case
[1, 58]. This pattern of striatal pathology appears to be
unique to our case as it has not been described in the
context of other SNCA mutations (Table 2).
Hippocampal sclerosis with severe neuronal loss
affecting CA1 and the subiculum is a feature of many
neurodegenerative diseases and is often associated with
TDP-43 immunoreactive inclusions in residual neurons in
these regions and elsewhere [64]. TDP-43 pathology is
reported to be frequent in DLB cases, but is considerably
rarer in MSA and in PD [3, 24, 30, 53]. While we observed
sparse TDP-43-positive inclusions in these areas, the
overall pattern of neuronal loss, being most severe in CA2/
3, did not resemble typical hippocampal sclerosis. Of
particular note was the abundance of TDP-43 immunore-
active NCIs in the caudate and putamen, regions also
vulnerable to TDP-43 pathology in FTLD-TDP [9]. We did
not observe TDP-43-positive inclusions in neocortex or
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brainstem motor nuclei. A further neuropathological fea-
ture, which may be distinctive in the G51D a-synuclein
mutation, is the distribution of neocortical a-synuclein
pathology. In PD, MSA and other SNCA mutations,
a-synuclein pathology is predominantly found in the deep
cortical laminae (Table 2) [19, 26, 27, 48, 72, 77] com-
pared with our observation of severe involvement of both
the superficial and deep cortical layers.
We further investigated the nature of intracellular
inclusions and Gallyas silver impregnation indicated the
presence of fibrillar protein. Phosphorylation of a-synuc-
lein at Ser129 is a feature of LB pathology and may
promote oligomerisation, while phosphorylation at Y125
may increase protein fibrillisation of a-synuclein [11, 29,
54]. Using immunofluorescence, we showed phosphoryla-
tion of a-synuclein at both Y125 and Ser129. Although the
majority of neuronal and glial inclusions were immunore-
active for p62 and ubiquitin, a proportion remained
unstained and these possibly represented an early phase of
inclusion formation [40, 41, 44]. A varying degree of tau
pathology has been reported in cases of SNCA mutation or
multiplication sometimes co-localising with a-synuclein in
neuronal inclusions [19, 27, 32, 48, 57, 72, 84]. We report
tau pathology in the hippocampal formation and entorhinal
cortex corresponding to Braak and Braak stage II, but with
additional involvement of the DF. Phosphorylated tau
co-localised with a subpopulation of neuronal a-synuclein
inclusions, particularly in the CA1 and DF. A relationship
between tau and both the levels and aggregation state of
a-synuclein, such that greater numbers of tau-positive
inclusions may increase a-synuclein pathology, is well
described [14, 15, 25, 46]. More recently, it has been
shown that a-synuclein oligomers can seed tau aggregation
in vitro and this may explain the occurrence of tau in a
proportion of a-synuclein-containing inclusions [45].
The defining neuropathological hallmark of MSA is the
presence of a-synuclein-containing GCIs coupled with
neurodegeneration in the striatonigral and/or olivoponto-
cerebellar regions [79]. The mechanism of GCI formation is
currently unknown and mature oligodendrocytes are not
thought to express a-synuclein under normal circumstances
[76]. Evidence of GCI-like pathology in cases of SNCA
multiplication [27, 57], A53T mutation [48] and in this case
of G51D mutation, provide a strong link between these
mutations and the pathological mechanisms of MSA. One
of the earliest stages of MSA pathogenesis may involve the
overexpression or aberrant localisation of a-synuclein in
oligodendrocytes, where it becomes fibrillar [69] and forms
GCIs [39]. Greater understanding of the effect of the G51D
and A53T mutations and SNCA multiplication may shed
further light on the pathological cascades, which result in
GCI formation. The data presented indicate that G51D
SNCA mutation results in a neuropathological profile, which
shares some neuropathological features of both PD and
MSA and, therefore understanding the consequences of this
mutation, has the potential to provide greater insight into
the role of a-synuclein mutation or dysfunction in the
pathogenesis of PD and also MSA. Understanding the
biology of this G51D SNCA mutation could help us to target
pathways in PD, MSA and other synucleinopathies, which
lead to neuronal and glial a-synuclein accumulation.
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